IGC Pharma (IGC) EBITDA (2010 - 2025)

IGC Pharma (IGC) has reported EBITDA for 16 consecutive years, with -$2.9 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, EBITDA fell 64.72% year-over-year to -$2.9 million in Q3 2025; TTM through Sep 2025 was -$9.5 million, a 1.97% decrease from a year earlier, with the FY2026 full-year figure at -$2.5 million, up 66.99% from the prior year.
• EBITDA was -$2.9 million for Q3 2025 at IGC Pharma, up from -$3.3 million in the prior quarter.
• Over five years, EBITDA peaked at -$1.4 million in Q1 2025 and troughed at -$6.5 million in Q1 2022.
• A 5-year average of -$2.8 million and a median of -$2.5 million in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA sank 159.43% in 2021 and jumped 46.27% in 2024, its largest moves.
• Over 5 years, EBITDA stood at -$2.4 million in 2021, then increased by 4.49% to -$2.3 million in 2022, then tumbled by 31.61% to -$3.0 million in 2023, then jumped by 37.36% to -$1.9 million in 2024, then plunged by 54.37% to -$2.9 million in 2025.
• The last three EBITDA figures came in at -$2.9 million (Q3 2025), -$3.3 million (Q2 2025), and -$1.4 million (Q1 2025), per Business Quant data.